Notably, JAK1 inhibitors, including tofacitinib, ruxolitinib, and pacritinib, have been broadly investigated in conditions involving chronic inflammation and hematological malignancies, with fewer evaluations in patients with solid tumors 47. This evidence concerns the gene JAK1 and hematologic disorder.